Antisoma leukaemia treatment to be fast-tracked
Thu 03 Jun 2010
 
LONDON (SHARECAST) - Cancer drug developer Antisoma’s Leukaemia treatment AS1413 has been granted Fast Track designation by the US Food and Drug Administration (FDA).

The Fast Track programme affords drugs that have shown the potential to meet an unmet medical need in serious or life-threatening diseases a speedier review process than would otherwise be the case.

‘We're very pleased to have gained FDA Fast Track status for AS1413,’ said Antisoma chief executive Glyn Edwards.

‘This drug could represent a major advance in the options available to patients with secondary AML [acute myeloid leukaemia], and we look forward to completing the ongoing phase III trial and sharing the data with FDA and other regulators.’ 

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=3495656
 

Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia

http://finance.yahoo.com/news/...ns-FDA-iw-55357026.html?x=0&.v=1